The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo
Open accessAbstract
Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor in clinical trials as a cancer therapy that has been recently shown to block human immunodeficiency virus Tat transactivation and viral replication through inhibition of positive transcription elongation factor b (P-TEFb). Flavopiridol is the most potent P-TEFb inhibitor reported and the first Cdk inhibitor that is not competitive with ATP. We examined the ability of flavopiridol to inhibit P-TEFb (Cdk9/cyclin T1) phosphorylation of both RNA polymerase II and the large subunit of the 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) sensitivity-inducing factor and found that the IC(50) determined was directly related to the concentration of the enzyme. We concluded that the flavonoid associates with P-TEFb with 1:1 stoichiometry even at concentrations of enzyme in the low nanomolar range. These results indicate that the apparent lack of competition with ATP could be caused by a very tight binding of the drug. We developed a novel immobilized P-TEFb assay and demonstrated that the drug remains bound for minutes even in the presence of high salt. Flavopiridol remained bound in the presence of a 1000-fold excess of the commonly used inhibitor DRB, suggesting that the immobilized P-TEFb could be used in a simple screening assay that would allow the discovery or characterization of compounds with binding properties similar to flavopiridol. Finally, we compared the ability of flavopiridol and DRB to inhibit transcription in vivo using nuclear run-on assays and concluded that P-TEFb is required for transcription of most RNA polymerase II molecules in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wei, P., Garber, M. E., Fang, S.-M., Fischer, W. H., & Jones, K. A. (1998) · Cell · doi:10.1016/s0092-8674(00)80939-3 · Cited by 1,249
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro
Zhu, Y., Pe’ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T., Amendt, B., Mathews, M. B., & Price, D. H. (1997) · Genes & Development · doi:10.1101/gad.11.20.2622 · Cited by 696
Self-citationP-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II
Price, D. H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2629-2634.2000 · Cited by 679
Self-citationCarlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro
Mancebo, H. S. Y., Lee, G., Flygare, J., Tomassini, J., Luu, P., Zhu, Y., Peng, J., Blau, C., Hazuda, D., Price, D., et al. (1997) · Genes & Development · doi:10.1101/gad.11.20.2633 · Cited by 544
Self-citationIdentification of multiple cyclin subunits of human P-TEFb
Peng, J., Zhu, Y., Milton, J. T., & Price, D. H. (1998) · Genes & Development · doi:10.1101/gad.12.5.755 · Cited by 519
Self-citationDe Azevedo, W. F., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., & Kim, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2735 · Cited by 496
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Self-citation
Cited by
Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., & Ozato, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.027 · Cited by 1,291
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Controlling the elongation phase of transcription with P-TEFb
Peterlin, B. M., & Price, D. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.014 · Cited by 1,144
Self-citationRecruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,138
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
The Long Noncoding RNAs NEAT1 and MALAT1 Bind Active Chromatin Sites
West, J. A., Davis, C. P., Sunwoo, H., Simon, M. D., Sadreyev, R. I., Wang, P. I., Tolstorukov, M. Y., & Kingston, R. E. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.07.012 · Cited by 709
Kaikkonen, M. U., Spann, N. J., Heinz, S., Romanoski, C. E., Allison, K. A., Stender, J. D., Chun, H. B., Tough, D. F., Prinjha, R. K., Benner, C., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.07.010 · Cited by 672
“We initially tested two different elongation inhibitors: the cyclin-dependent kinase (cdk) inhibitor flavopiridol, which at low concentrations preferentially inhibits the Cdk9 activity of P-TEFb (Chao and Price, 2001); and IBET151, a selective inhibitor of BET (bromodomain and extra terminal domain) protein binding to…”
BackgroundMethodInfluentialStock, J. K., Giadrossi, S., Casanova, M., Brookes, E., Vidal, M., Koseki, H., Brockdorff, N., Fisher, A. G., & Pombo, A. (2007) · Nature Cell Biology · doi:10.1038/ncb1663 · Cited by 650
Jonkers, I., Kwak, H., & Lis, J. T. (2014) · eLife · doi:10.7554/elife.02407 · Cited by 581
Defining mechanisms that regulate RNA polymerase II transcription in vivo
Fuda, N. J., Ardehali, M. B., & Lis, J. T. (2009) · Nature · doi:10.1038/nature08449 · Cited by 576
Inhibiting eukaryotic transcription: which compound to choose? How to evaluate its activity
Bensaude, O. (2011) · Transcription · doi:10.4161/trns.2.3.16172 · Cited by 574
RNA Polymerase II Elongation Control
Zhou, Q., Li, T., & Price, D. H. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052610-095910 · Cited by 571
Self-citationPromoter-proximal pausing of RNA polymerase II: a nexus of gene regulation
Core, L., & Adelman, K. (2019) · Genes & Development · doi:10.1101/gad.325142.119 · Cited by 568
Pharmacological inhibitors of cyclin-dependent kinases
Knockaert, M., Greengard, P., & Meijer, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02071-0 · Cited by 537
Breaking barriers to transcription elongation
Saunders, A., Core, L. J., & Lis, J. T. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1981 · Cited by 506
The RNA Polymerase II Carboxy-Terminal Domain (CTD) Code
Eick, D., & Geyer, M. (2013) · Chemical Reviews · doi:10.1021/cr400071f · Cited by 470
Yik, J. H. N., Chen, R., Nishimura, R., Jennings, J. L., Link, A. J., & Zhou, Q. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00388-5 · Cited by 466
Chromatin-Bound Nuclear Pore Components Regulate Gene Expression in Higher Eukaryotes
Capelson, M., Liang, Y., Schulte, R., Mair, W., Wagner, U., & Hetzer, M. W. (2010) · Cell · doi:10.1016/j.cell.2009.12.054 · Cited by 443
He, N., Liu, M., Hsu, J., Xue, Y., Chou, S., Burlingame, A., Krogan, N. J., Alber, T., & Zhou, Q. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.04.013 · Cited by 395
Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-020735 · Cited by 390
RNA promotes the formation of spatial compartments in the nucleus
Quinodoz, S. A., Jachowicz, J. W., Bhat, P., Ollikainen, N., Banerjee, A. K., Goronzy, I. N., Blanco, M. R., Chovanec, P., Chow, A., Markaki, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.10.014 · Cited by 388
Natural Products/Bioactive Compounds as a Source of Anticancer Drugs
Asma, S. T., Acaroz, U., Imre, K., Morar, A., Shah, S. R. A., Hussain, S. Z., Arslan-Acaroz, D., Demirbas, H., Hajrulai-Musliu, Z., Istanbullugil, F. R., et al. (2022) · Cancers · doi:10.3390/cancers14246203 · Cited by 378
Chen, K., Chen, Z., Wu, D., Zhang, L., Lin, X., Su, J., Rodriguez, B., Xi, Y., Xia, Z., Chen, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3385 · Cited by 373
Mayer, A., di Iulio, J., Maleri, S., Eser, U., Vierstra, J., Reynolds, A., Sandstrom, R., Stamatoyannopoulos, J. A., & Churchman, L. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.010 · Cited by 367
CDK8 is a positive regulator of transcriptional elongation within the serum response network
Donner, A. J., Ebmeier, C. C., Taatjes, D. J., & Espinosa, J. M. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1752 · Cited by 371
Myeloid cell factor–1 is a critical survival factor for multiple myeloma
Zhang, B., Gojo, I., & Fenton, R. G. (2002) · Blood · doi:10.1182/blood.v99.6.1885 · Cited by 367
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Yecies, D., Carlson, N. E., Deng, J., & Letai, A. (2010) · Blood · doi:10.1182/blood-2009-07-233304 · Cited by 360
RNA helicase DDX21 coordinates transcription and ribosomal RNA processing
Calo, E., Flynn, R. A., Martin, L., Spitale, R. C., Chang, H. Y., & Wysocka, J. (2015) · Nature · doi:10.1038/nature13923 · Cited by 324
Crystal structure of HIV-1 Tat complexed with human P-TEFb
Tahirov, T. H., Babayeva, N. D., Varzavand, K., Cooper, J. J., Sedore, S. C., & Price, D. H. (2010) · Nature · doi:10.1038/nature09131 · Cited by 314
Self-citationNELF and DSIF cause promoter proximal pausing on the hsp70 promoter in Drosophila
Wu, C.-H., Yamaguchi, Y., Benjamin, L. R., Horvat-Gordon, M., Washinsky, J., Enerly, E., Larsson, J., Lambertsson, A., Handa, H., & Gilmour, D. (2003) · Genes & Development · doi:10.1101/gad.1091403 · Cited by 313
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3139 · Cited by 301
Bancerek, J., Poss, Z. C., Steinparzer, I., Sedlyarov, V., Pfaffenwimmer, T., Mikulic, I., Dölken, L., Strobl, B., Müller, M., Taatjes, D. J., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.017 · Cited by 297
Regulation of RNA polymerase II activation by histone acetylation in single living cells
Stasevich, T. J., Hayashi-Takanaka, Y., Sato, Y., Maehara, K., Ohkawa, Y., Sakata-Sogawa, K., Tokunaga, M., Nagase, T., Nozaki, N., McNally, J. G., et al. (2014) · Nature · doi:10.1038/nature13714 · Cited by 290
The Control of HIV Transcription: Keeping RNA Polymerase II on Track
Ott, M., Geyer, M., & Zhou, Q. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.11.002 · Cited by 286
Gomes, N. P., Bjerke, G., Llorente, B., Szostek, S. A., Emerson, B. M., & Espinosa, J. M. (2006) · Genes & Development · doi:10.1101/gad.1398206 · Cited by 266
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
Evidence for DNA-mediated nuclear compartmentalization distinct from phase separation
McSwiggen, D. T., Hansen, A. S., Teves, S. S., Marie-Nelly, H., Hao, Y., Heckert, A. B., Umemoto, K. K., Dugast-Darzacq, C., Tjian, R., & Darzacq, X. (2019) · eLife · doi:10.7554/elife.47098 · Cited by 265
Nechaev, S., & Adelman, K. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.11.001 · Cited by 265
Myc Recruits P-TEFb to Mediate the Final Step in the Transcriptional Activation of the cad Promoter
Eberhardy, S. R., & Farnham, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207441200 · Cited by 262
Zhou, Q., & Yik, J. H. N. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00011-06 · Cited by 261
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
Chen, R., Keating, M. J., Gandhi, V., & Plunkett, W. (2005) · Blood · doi:10.1182/blood-2005-04-1678 · Cited by 259
The Molecular Basis for Human Immunodeficiency Virus Latency
Mbonye, U., & Karn, J. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041646 · Cited by 182
Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy
Liang, K., Smith, E. R., Aoi, Y., Stoltz, K. L., Katagi, H., Woodfin, A. R., Rendleman, E. J., Marshall, S. A., Murray, D. C., Wang, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.027 · Cited by 124
A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation
Barboric, M., & Peterlin, B. M. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030076 · Cited by 106
Role of viral regulatory and accessory proteins in HIV-1 replication
Seelamgari, A. (2004) · Frontiers in Bioscience · doi:10.2741/1403 · Cited by 98
“Flavopiridol can inhibit the cyclinT1/CDK9 complex (78) as well as CDK2 (79).”
BackgroundChen, H., Du, G., Song, X., & Li, L. (2017) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2017.02.003 · Cited by 85
RNA damage compartmentalization by DHX9 stress granules
Zhou, Y., Panhale, A., Shvedunova, M., Balan, M., Gomez-Auli, A., Holz, H., Seyfferth, J., Helmstädter, M., Kayser, S., Zhao, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.028 · Cited by 83
Fitz, J., Neumann, T., & Pavri, R. (2018) · The EMBO Journal · doi:10.15252/embj.201797965 · Cited by 74
“Next, the kinases P-TEFb (Marshall & Price, 1995; Marshall et al , 1996; Chao & Price, 2001; Peterlin & Price, 2006) and Cdk12 (Bartkowiak et al , 2010; Liang et al , 2015) are recruited, which phosphorylate Pol II at serine 2 of its C-terminal domain, Spt5 and NELF (Jonkers & Lis, 2015).”
Identifying the Membrane Proteome of HIV-1 Latently Infected Cells
Berro, R., de la Fuente, C., Klase, Z., Kehn, K., Parvin, L., Pumfery, A., Agbottah, E., Vertes, A., Nekhai, S., & Kashanchi, F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606324200 · Cited by 72
Muniz, L., Deb, M. K., Aguirrebengoa, M., Lazorthes, S., Trouche, D., & Nicolas, E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.006 · Cited by 56
Adult Stem Cells Exhibit Global Suppression of RNA Polymerase II Serine-2 Phosphorylation
Freter, R., Osawa, M., & Nishikawa, S.-I. (2010) · Stem Cells · doi:10.1002/stem.476 · Cited by 43
Subcellular mRNA kinetic modeling reveals nuclear retention as rate-limiting
(2024) · doi:10.1038/s44320-024-00073-2 · Cited by 14
Metadata
- Authors
- Chao, S.-H., & Price, D. H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-08
- Volume
- 276
- Issue
- 34
- Pages
- 31793-31799
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2081567150
- Cited by
- 621
- References
- 31
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.